# Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)

> **NCT05124561** · PHASE3 · WITHDRAWN · sponsor: **CanSino Biologics Inc.**

## Conditions studied

- COVID-19

## Interventions

- **BIOLOGICAL:** Recombinant COVID-19 vaccine (adenovirus type 5 vector) for Inhalation (Ad5-nCoV-IH)
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05124561
- **Lead sponsor:** CanSino Biologics Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12-15
- **Primary completion:** 2022-04-15
- **Final completion:** 2022-08-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The trial protocol was not approved by the regulatory authorities.
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05124561

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05124561, "Study to Evaluate the inHaled Recombinant COVID-19 Vaccine (Adenovirus Type 5 Vector) On the Protective-Efficacy in Adults (SeiHOPE)". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05124561. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*